- Home
- ALNY vs FOXA Comparison
ALNY vs FOXA Comparison
Compare ALNY & FOXA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ALNY | FOXA |
|---|---|---|
| Founded | 2002 | 2018 |
| Country | United States | United States |
| Employees | 115 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Broadcasting |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.2B | 28.4B |
| IPO Year | 2004 | 2018 |
Fundamental Metrics
Financial Performance| Metric | ALNY | FOXA |
|---|---|---|
| Price | $253.74 | $62.11 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 28 | 15 |
| Target Price | ★ $471.00 | $71.57 |
| AVG Volume (30 Days) | 1.3M | ★ 4.1M |
| Earning Date | 04-30-2026 | 05-11-2026 |
| Dividend Yield | N/A | ★ 0.89% |
| EPS Growth | ★ 206.88 | N/A |
| EPS | 2.71 | ★ 3.84 |
| Revenue | $1,037,418,000.00 | ★ $14,913,000,000.00 |
| Revenue This Year | $52.67 | $1.78 |
| Revenue Next Year | $31.48 | $4.24 |
| P/E Ratio | $93.31 | ★ $16.34 |
| Revenue Growth | ★ 22.88 | 6.72 |
| 52 Week Low | $197.81 | $48.34 |
| 52 Week High | $495.55 | $76.39 |
Technical Indicators
Market Signals| Indicator | ALNY | FOXA |
|---|---|---|
| Relative Strength Index (RSI) | 53.41 | 40.54 |
| Support Level | $236.00 | $61.25 |
| Resistance Level | $272.08 | $65.33 |
| Average True Range (ATR) | 8.32 | 1.43 |
| MACD | 0.83 | -0.53 |
| Stochastic Oscillator | 79.31 | 10.91 |
Price Performance
Historical ComparisonAbout ALNY Alnylam Pharmaceuticals Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam's commercial RNAi therapeutic products include Onpattro and Amvuttra (for hATTR amyloidosis), Givlaari (for acute hepatic porphyria), and Oxlumo (for primary hyperoxaluria type 1), all developed and commercialized by Alnylam. Plus, Leqvio (for hypercholesterolemia) and Qfitlia (for hemophilia A or B), which are being commercialized by Alnylam's partners, Novartis and Sanofi, respectively. It also has several clinical programs across various therapeutic areas, including cardio-metabolic diseases, neuroscience, and hematology.
About FOXA Fox Corporation
Fox operates in two segments: cable networks and television. Cable networks primarily includes Fox News, Fox Business, and several pay-TV sports stations. Television primarily includes the Fox broadcast network, 29 owned and operated local television stations, of which 18 are affiliated with the Fox network, and streaming platform Tubi, which is not subscription-based and is completely ad-supported. Fox effectively sold most of its entertainment assets to Disney in 2019, so it no longer creates entertainment content and relies heavily on live news and sports, with nearly all tied to the pay-TV bundle. The Murdoch family controls Fox.